SCOTUS' Pass On Generic Labeling Case Puts FDA Rule In Spotlight

The Supreme Court's decision this week not to take up a lower court's ruling that a generic drug company should have immediately updated its product label to include new safety data puts the spotlight back on FDA, which is already facing intense pressure from generic drug makers not to finalize a proposed rule that would impose similar labeling requirements. Generic drug makers last year urged lawmakers to intervene and also signaled they would sue if FDA moved forward with the...